Type I interferon in systemic lupus erythematosus and other autoimmune diseases - PubMed (original) (raw)

Review

Type I interferon in systemic lupus erythematosus and other autoimmune diseases

Jacques Banchereau et al. Immunity. 2006 Sep.

Free article

Abstract

Different genetic alterations may lead to type I interferon (IFN) overproduction in human systemic lupus erythematosus (SLE). The increased bioavailability of type I IFN contributes to peripheral tolerance breakdown through the activation of immature myeloid dendritic cells (mDCs). IFN-matured mDCs activate autoreactive T cells. These cells, together with plasmacytoid DCs, help expand autoreactive B cells. IFN-matured DCs also activate cytotoxic CD8+ T cells, possibly increasing apoptotic cell availability. The capture of apoptotic cells by mDCs and of nucleic acid-containing immune complexes by plasmacytoid DCs and B cells amplifies the autoimmune reaction leading to disease manifestations. Genetic alterations in lineages other than B cells might explain other autoimmune syndromes where type I IFNs appear to be involved.

PubMed Disclaimer

Similar articles

• A compass that points to lupus: genetic studies on type I interferon pathway.
  Kyogoku C, Tsuchiya N. Kyogoku C, et al. Genes Immun. 2007 Sep;8(6):445-55. doi: 10.1038/sj.gene.6364409. Epub 2007 Jun 21. Genes Immun. 2007. PMID: 17581625 Review.
• Systemic lupus erythematosus: all roads lead to type I interferons.
  Pascual V, Farkas L, Banchereau J. Pascual V, et al. Curr Opin Immunol. 2006 Dec;18(6):676-82. doi: 10.1016/j.coi.2006.09.014. Epub 2006 Oct 2. Curr Opin Immunol. 2006. PMID: 17011763 Review.
• Type-I interferons and systemic lupus erythematosus.
  Koutouzov S, Mathian A, Dalloul A. Koutouzov S, et al. Autoimmun Rev. 2006 Oct;5(8):554-62. doi: 10.1016/j.autrev.2006.05.002. Epub 2006 Jun 27. Autoimmun Rev. 2006. PMID: 17027892 Review.

Cited by

• Type-I interferon is critical for FasL expression on lung cells to determine the severity of influenza.
  Fujikura D, Chiba S, Muramatsu D, Kazumata M, Nakayama Y, Kawai T, Akira S, Kida H, Miyazaki T. Fujikura D, et al. PLoS One. 2013;8(2):e55321. doi: 10.1371/journal.pone.0055321. Epub 2013 Feb 8. PLoS One. 2013. PMID: 23408968 Free PMC article.
• Chemoproteomic development of SLC15A4 inhibitors with anti-inflammatory activity.
  Chiu TY, Lazar DC, Wang WW, Wozniak JM, Jadhav AM, Li W, Gazaniga N, Theofilopoulos AN, Teijaro JR, Parker CG. Chiu TY, et al. Nat Chem Biol. 2024 Aug;20(8):1000-1011. doi: 10.1038/s41589-023-01527-8. Epub 2024 Jan 8. Nat Chem Biol. 2024. PMID: 38191941 Free PMC article.
• RING finger protein 11 targets TBK1/IKKi kinases to inhibit antiviral signaling.
  Charoenthongtrakul S, Gao L, Parvatiyar K, Lee D, Harhaj EW. Charoenthongtrakul S, et al. PLoS One. 2013;8(1):e53717. doi: 10.1371/journal.pone.0053717. Epub 2013 Jan 7. PLoS One. 2013. PMID: 23308279 Free PMC article.
• Type I Interferon Production of Plasmacytoid Dendritic Cells under Control.
  Bencze D, Fekete T, Pázmándi K. Bencze D, et al. Int J Mol Sci. 2021 Apr 18;22(8):4190. doi: 10.3390/ijms22084190. Int J Mol Sci. 2021. PMID: 33919546 Free PMC article. Review.
• Plasmacytoid dendritic cells in atherosclerosis.
  Döring Y, Zernecke A. Döring Y, et al. Front Physiol. 2012 Jun 28;3:230. doi: 10.3389/fphys.2012.00230. eCollection 2012. Front Physiol. 2012. PMID: 22754539 Free PMC article.

Publication types

MeSH terms

Substances

Grants and funding

• P01 CA084512/CA/NCI NIH HHS/United States
• R01 AR46589-01/AR/NIAMS NIH HHS/United States
• R01 CA078846/CA/NCI NIH HHS/United States
• U19 AI057234-02/AI/NIAID NIH HHS/United States

LinkOut - more resources

• Full Text Sources

  • Elsevier Science
  • Ovid Technologies, Inc.

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information

• Research Materials

  • NCI CPTC Antibody Characterization Program